Find Academic Supervisors

Ludvig Magne SollidView profile

Professor

• Immunology
• Autoimmune Diseases
• Celiac Disease
• +4 more

Ludvig Magne Sollid is a Professor in the Department of Immunology at the University of Oslo, affiliated with the Faculty of Medicine. His research focuses on immunological mechanisms underlying celiac disease, gluten-related autoimmunity, and T-cell biology. He leads the Functional Immunogenetics group and the K.G. Jebsen Coeliac Disease Research Centre, contributing to advancements in understanding disease pathogenesis and diagnostic methods. Research Areas: Celiac disease immunology, transglutaminase activity, autoimmune mechanisms, gluten peptide interactions, and mucosal immune responses. Key Collaborations: Extensive international collaborations in immunology, gastroenterology, and clinical research. Research Interests Dr. Sollid's work centers on unraveling the interplay between genetics, environmental triggers (e.g., gluten), and immune responses in celiac disease. His lab investigates B-cell and T-cell activation pathways, autoantibody formation, and proteomic biomarkers for disease diagnosis and monitoring. Recent studies highlight novel mouse models, organoid systems, and clinical trials evaluating gluten challenge effects. Publications His articles emphasize celiac disease mechanisms, immunopathology, and diagnostic tools. Notable themes include B-cell receptor functions, transglutaminase 2 roles, and gluten peptide-specific T-cell responses. Collaborative work spans epidemiology, proteomics, and clinical trials. Awards and Grants No specific awards listed, but his research is supported by major grants from the K.G. Jebsen Foundation and international funding bodies. Labs/Teams He directs the Functional Immunogenetics group and the Jebsen Coeliac Disease Research Centre, fostering interdisciplinary projects in immunology and clinical research.

Wei LiView profile

Professor

• Ligandomics
• Angiogenesis
• Ocular Vascular Diseases
• +5 more

Wei Li, Ph.D., is a Professor and Knights Templar Eye Foundation Presidential Chair in Ophthalmology at Baylor College of Medicine. His research focuses on ligandomics, a revolutionary technology for identifying disease-selective ligands and developing targeted therapies for ocular vascular diseases such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization. His lab pioneered function-first and therapy-first approaches to characterize ligands like secretogranin III (Scg3), which selectively regulate pathological angiogenesis without affecting healthy vasculature. Education: PhD (University of Nebraska Medical Center, 1991), MS (Zhejiang University College of Medicine, 1986), BSc (Zhangjiang University College of Pharmacy, 1983) Research Themes: Neurovascular crosstalk, anti-angiogenic therapies, ligandomics-driven drug discovery Dr. Li leads NIH-funded projects to advance next-generation ligandomics technology, develop anti-Scg3 therapies, and investigate disease mechanisms in ocular diseases. His work bridges basic science and clinical translation, with patents on Scg3-neutralizing antibodies and ligandomics methodologies. Grants & Funding: NIH R43EY031643-01A1: Next-generation ligandomics technology ($226,255; 2020–2021) NIH/NEI R24EY028764: Anti-retinopathy of prematurity therapy ($9.1M; 2019–2023) American Diabetes Association 1-18-IBS-172: Scg3 as a diabetic retinopathy target ($345K; 2018–2020) Intellectual Property: Patents on Scg3-neutralizing antibodies and ligandomics techniques (e.g., US 8,754,013; pending applications).

Brent BillView profile

Associate Professor

• Molecular Biology
• Developmental Biology
• Neuroscience
• +3 more

Brent Bill is an Associate Professor of Biology at the University of Texas at Tyler (UT Tyler). His academic journey includes a Ph.D. in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota (2008), an M.S. in Biotechnology, and a B.S. in Biology from Illinois State University (2002 and 1999 respectively). Prior to his current role, he held positions as a Postdoctoral Researcher at UCLA's Semel Institute for Neuroscience (2008–2014) and a Lecturer at UCLA's Department of Life Sciences (2014). Bill’s research focuses on neurodevelopmental disorders, zebrafish models, and genetic mechanisms underlying behaviors and neurological conditions. He has pioneered studies using zebrafish to investigate autism spectrum disorder (ASD) risk genes like CNTNAP2 and CYFIP1, as well as Parkinson’s disease modeling through dopamine pathway studies. His work integrates molecular genetics, behavioral assays, and bioengineering approaches. Notable contributions include developing tools for optic fissure closure assessment and characterizing virus-like particle (VLP) toxicity. His research spans topics from neuropharmacology (nicotinic receptors) to environmental engineering (graywater treatment systems). Labs/Teams: Bill has been affiliated with UCLA’s Center for Autism Research and Treatment under Dr. Daniel Geschwind’s mentorship. His UT Tyler lab likely continues neurobehavioral and developmental studies using zebrafish systems. Advising & Grants: His postdoctoral work was supported by the AP Giannini Foundation (2009–2012). He advises students through UT Tyler’s undergraduate courses in Cell Biology and Developmental Biology, emphasizing hands-on lab training and genetics education.

Johannes YehView profile

Academic

• Cell Signaling
• Cancer Biology
• Biomolecular Engineering
• +3 more

Johannes Yeh is a Research Associate Professor and Director of the Antibody and Phage Display Shared Resource at Cold Spring Harbor Laboratory (CSHL). He holds the rank of Research Associate Professor within the CSHL Cancer Center. His primary affiliation is with CSHL's Cancer Center, focusing on cellular communication mechanisms and therapeutic development for cancer and other diseases. Yeh earned his Ph.D. in 2006 from the University of Cambridge and completed postdoctoral training at Harvard University. His academic career includes roles as a Research Assistant Professor (2016–2022) and Scientist/Lab Head at Merck (2014–2016). His research focuses on cell signaling dysregulation in diseases like cancer, leveraging biomolecular engineering to develop targeted therapies. Key areas include protein engineering, antibody-based therapeutics, and mechanisms of targeted protein degradation. His lab also explores the tumor microenvironment and drug discovery strategies. Notable achievements include developing macrocycle-based degraders, identifying tumor-specific antibodies, and characterizing NETs' role in cancer dormancy. He has received awards such as the Susan G. Komen Fellowship (2009) and MRC Technology Invention Award (2006). Yeh oversees the Antibody & Phage Display Shared Resource, supporting CSHL's research community with advanced biologics technologies. His work bridges basic science and translational medicine, with over 20 peer-reviewed publications and multiple patents.

Mona BatishView profile

Associate Professor

• RNA Biology
• Gene Expression Regulation
• Cancer Biomarkers
• +3 more

Mona Batish is an Associate Professor in the Medical & Molecular Sciences department at the University of Delaware's College of Health Sciences. Her research focuses on RNA biology, particularly exploring RNA processing, transport, and localization in health and disease. She investigates the role of coding and non-coding RNAs as diagnostic biomarkers, with a current emphasis on Ewing’s Sarcoma, a pediatric bone cancer. Her work integrates single-molecule imaging and molecular tools to study RNA dynamics. Dr. Batish holds a BSc (Honors), MSc (Honors), and PhD from Panjab University and Rutgers University, respectively. She leads the Batish Lab, which collaborates widely to advance understanding of RNA regulation and EV-mediated communication. Notable achievements include the NIH Director’s Early Independence Award (2012) and tenure (2022). Her research spans RNA trafficking in extracellular vesicles, development of diagnostic assays, and molecular mechanisms of cancer progression. Recent projects include studies on circRNAs in cerebral palsy and HIV-associated RNA packaging. She actively mentors students and contributes to initiatives like the STAR Tower research hub.

Joanne Clark-MatottView profile

Teaching Professor

• Neurobiology
• Neuroscience
• Neurodegenerative Diseases
• +3 more

Dr. Joanne (Jo) Clark-Matott is a Teaching Professor in the Department of Human Evolutionary Biology at Harvard University, located at the Peabody Museum, 5th Floor. Her research focuses on neurodegenerative mechanisms, mitochondrial biology, and cellular stress responses, with particular emphasis on Parkinson’s disease and Alzheimer’s disease models. Her work explores topics such as the role of extracellular Hsp90α in neuroprotection, mitochondrial DNA mutations in aging, and biomarkers of disease progression. She employs techniques like metabolomics, biochemical analysis, and mouse models to investigate these areas. Key themes include oxidative stress modulation, drug efficacy (e.g., pioglitazone, rapamycin), and genetic influences on neurodegeneration. Dr. Clark-Matott’s publications reflect interdisciplinary approaches, combining neurobiology, genetics, and pharmacology to address fundamental questions in neuroprotection and disease modeling. She is affiliated with Harvard’s Faculty of Arts and Sciences and contributes to teaching and research in human evolutionary biology. While no specific awards are listed, her work demonstrates sustained engagement with high-impact research topics in neuroscience and mitochondrial dysfunction. Her research location at the Peabody Museum underscores collaboration with Harvard’s broader academic and museum networks.

• Neuroscience
• Neurodegenerative Disorders
• Blood-Brain Barrier
• +3 more

Abhay Sagare, PhD, is an Assistant Professor of Research Physiology & Neuroscience at the University of Southern California. He holds the role of Assistant Director at the Biomarkers Assay Core. His research focuses on neurovascular mechanisms in neurodegenerative disorders, particularly Alzheimer's disease, with an emphasis on blood-brain barrier dysfunction, amyloid-β clearance, and biomarker development. Key areas include pericyte biology, cerebrovascular integrity, and the intersection of vascular health with cognitive decline. His work integrates clinical studies, molecular biology, and translational research. Recent studies highlight his contributions to understanding the role of blood-brain barrier breakdown in cognitive dysfunction, the utility of CSF biomarkers like soluble PDGFRß, and the impact of genetic mutations (e.g., PSEN1) on disease progression. His publications often explore therapeutic strategies targeting neurovascular dysfunction, such as the anti-malaria drug artesunate's effects on amyloid pathology. Publications (2023–2025) consistently address biomarker discovery, vascular mechanisms in dementia, and translational applications of neurovascular research. His work bridges basic science and clinical practice, aiming to identify diagnostic and treatment targets for neurodegenerative diseases.

Christopher James BackhouseView profile

Professor

• Quantum Devices
• Biomedical Engineering
• MEMS/MOEMS
• +5 more

Dr. Christopher James Backhouse is a Professor of Electrical & Computer Engineering and a member of the Waterloo Institute of Nanotechnology at the University of Waterloo. He holds P.Eng. certification and has held academic roles at the University of Alberta (1999-2011) and the University of Waterloo since 2011. His research focuses on quantum devices, biomedical engineering, lab-on-chip technologies, and nanobiotechnology, with applications in medical diagnostics and CMOS integration. He leads the Applied Miniaturisation Laboratory (AML), emphasizing miniaturization and integration of technologies. Education: BSc in Physics (University of Alberta, 1985), MSc in Radio Astronomy (University of British Columbia, 1987), PhD in Electrical Engineering (University of British Columbia, 1992). Professional roles include Director of the Nanotechnology Engineering Program (2012-2014) and Adjunct Professorships at the University of Alberta. Research interests span lab-on-chip devices, quantum effects in biology, microfluidics, and remote sensing. Recent work includes developing low-cost diagnostic systems and exploring quantum nanobiotechnology. Awards include the Summit Award (2008) and National Engineering Project Award (2009). Teaching includes courses on nanoelectronics, nanobiotechnology, and capstone design projects. His lab collaborates with industry to advance technologies like handheld medical diagnostics and integrated CMOS systems.

• Regenerative Medicine
• Stem Cell Biology
• Cancer Stem Cells
• +7 more

Dr. Rebecca Lim is an Adjunct Associate Professor (Research) in Obstetrics & Gynaecology at Monash University, affiliated with Monash Health and The Ritchie Centre. She holds a PhD in Medicine and Pharmacology from the University of Western Australia, focusing on liver progenitor cells in chronic hepatitis. Her research group explores regenerative medicine, particularly amnion-derived stem-like cells and extracellular vesicles, with clinical translation in lung repair, stroke, and fibrotic diseases. She leads over 30 active research projects, including clinical trials for Crohn’s disease and stroke therapies. Key roles include Chief Investigator on multiple NHMRC and industry grants, and collaborations with institutions like Newcastle University and Exosome Biosciences. She sits on editorial boards for journals like Stem Cell Research & Therapy and advises organizations such as CCRM Australia. Lim has received awards including the Fielding Foundation Fellowship and International Society for Cell Therapies recognition. Research interests span regenerative medicine, stem cell biology, and translational therapies targeting chronic inflammation, fibrosis, and organ repair. Her lab’s work on amnion cells has advanced treatments for cirrhosis, pulmonary hypertension, and perianal fistulas. Ongoing projects include exosome-based therapies and novel cell-free regenerative approaches.

Johan HartmanView profile

Professor

• Precision Pathology
• Breast Cancer Therapy
• Digital Image Analysis
• +4 more

Professor Johan Hartman is a leading academic and clinician at Karolinska Institutet, serving as a Professor and Senior Consultant in the Department of Oncology-Pathology. His primary role combines research leadership in precision pathology with clinical expertise in breast pathology at Karolinska University Hospital. Hartman leads a research group focused on personalized breast cancer therapy through advanced technologies like AI-driven histopathology analysis, molecular genomics, and patient-derived tumor models. Education & Qualifications: Doctoral Degree (2008), Karolinska Institutet Medical Degree (2008), Karolinska Institutet Docent (2015), Karolinska Institutet Research Focus: Hartman’s lab pioneers innovations in precision medicine, particularly in predicting treatment responses using digital pathology, AI, and genomic profiling. Key areas include tumor heterogeneity, AI tools for diagnostic accuracy, and translational research linking molecular profiles to clinical outcomes. His group has developed clinical-grade AI systems for breast cancer risk stratification and tumor characterization. Publications & Impact: With over 100 peer-reviewed articles in high-impact journals (e.g., Science, Nature Communications), Hartman’s work emphasizes breast cancer therapy prediction, immune profiling, and molecular diagnostics. Recent studies include AI-driven TIL analysis, spatial transcriptomics, and genomic heterogeneity in tumors. Awards & Recognition: 2023 Karolinska Institutet Innovation Award 2022 Athena Prize (Vetenskapsrådet) 2016 Clinical Investigator Award (Swedish Cancer Society) Grants & Collaborations: Leading projects funded by Radiumhemmets Forskningsfonder, Vinnova, and industry partnerships Co-founder of Stratipath, a KI spin-off advancing precision pathology tools Labs & Teams: Hartman’s group includes postdocs, PhD students, and clinical researchers. Key members focus on AI in pathology, tumor modeling, and translational oncology. The team collaborates internationally on initiatives like the International Immuno-Oncology Biomarker Working Group.

• Biomaterials Engineering
• Tissue Engineering
• Microbial Biofilms
• +7 more

Tamara Rossy is a Postdoctoral Fellow at the Massachusetts Institute of Technology (MIT) within the Department of Mechanical Engineering, School of Engineering. Her research focuses on the intersection of biomaterials, microbial biofilms, and biomechanics, with an emphasis on understanding how bacteria interact with soft tissues and engineered systems. She explores topics such as biofilm-induced tissue damage, bacterial colonization dynamics, and applications in regenerative medicine. Her work integrates experimental and computational approaches to study complex biological systems, including tissue-engineered human airways and skeletal muscle models. Key areas include the mechanical interactions between bacteria, mucus, and epithelial tissues, as well as the development of novel biomaterials for adaptive tissue engineering. Rossy’s research has contributed to understanding fitness trade-offs in Pseudomonas aeruginosa infections and the biomechanical mechanisms underlying biofilm formation. Her studies on optogenetic skeletal muscle assays and microtopography-driven muscle actuators highlight her multidisciplinary approach to biomedical engineering challenges. Though not explicitly detailed in the provided text, her work likely involves collaborations with labs focused on biophysics, microbiology, and materials science. Grants and advising roles are not mentioned in the current data.

Nicholas NoinajView profile

Associate Professor

• Structural Biology
• Computational Biology
• Biophysics
• +5 more

Nicholas Noinaj is an Associate Professor in the Department of Biological Sciences at Purdue University's College of Science, focusing on structural and computational biology and biophysics. His research explores Gram-negative bacterial pathogenesis, with a focus on outer membrane protein biogenesis via the BAM complex, Toc75 in chloroplasts, and metal acquisition systems in Neisseria. Using X-ray crystallography, cryoEM, and functional assays, he bridges structural insights to drug discovery against pathogens. BA/BS in Chemistry/Mathematics, Berea College PhD in Biochemistry, University of Kentucky College of Medicine Postdoctoral Fellow, NIH/NIDDK His research spans three main areas: (1) BAM complex dynamics in outer membrane protein folding for Gram-negative bacteria; (2) TOC complex structure-function in chloroplasts; and (3) metal piracy mechanisms in pathogens like Neisseria. Structural methods include crystallography, cryoEM, and molecular dynamics simulations. His work has implications for antimicrobial resistance and therapeutic targeting. Key publications highlight conformational flexibility in BamA POTRA domains (2024), synthetic antigen binding fragments for TOC isolation (2023), DNA crystal engineering for molecular interactions (2023), and structural inhibition of NTMT1 (2023). Earlier works dissect BAM's hybrid-barrel mechanism (2021) and TdfH's zinc import (2022). 2020: Excellence in Research Award, Purdue University 2019: Showalter Faculty Scholar and Mentoring Award, College of Science 2018: Excellence in Research Award, Biological Sciences 2017: College of Science Team Award 2013 and 2012: Fellows Award for Research Excellence (FARE), NIH Funding sources include NIH/NIGMS, Purdue University EVPRP, Showalter Trust, NIH/NIAID, and Achaogen. He advises the Biology Graduate Student Association, Structural Biology Journal Club, and co-organizes the Tessman Symposium. His lab team includes Shubham, Swati, Yi, Dorothy, Nourin, Mengxi, Michelle, Linda, and Nick (2025 lab photo).

David TscharkeView profile

Research Fellow

• Virology
• Immunology
• Cellular Immunology
• +4 more

David Tscharke is a NHMRC Senior Research Fellow and Group Leader at The Australian National University's John Curtin School of Medical Research (JCSMR). He leads the Tscharke Group - Viruses and Immunity, focusing on viral pathogenesis, immune system interactions, and vaccine design. His work spans herpes simplex virus (HSV) latency, antigen presentation, and T cell immunology. He holds affiliations with the Division of Immunology and Infectious Diseases and collaborates with the Wen Group on computational biology. Education: PhD from University of Adelaide/IMVS Postdoctoral training at Oxford University and Imperial College London NIH experience in viral immunology Research interests include: HSV latency and reactivation mechanisms CD8+ T cell immunodominance hierarchies Antigen presentation dynamics Poxvirus vaccine development Publications focus on viral-host interactions, with recent work highlighting CRISPR-based poxvirus engineering and T cell epitope quantification. Awards include the Young Tall Poppy Award and NHMRC/ARC fellowships. Collaborations involve interdisciplinary teams exploring RNA-binding proteins in immune cell differentiation.

Alexander EckersleyView profile

Lecturer

• Extracellular Matrix Biology
• Proteomics
• Mass Spectrometry
• +5 more

Dr. Alexander Eckersley is a Lecturer in Skin Health at the Division of Musculoskeletal & Dermatological Sciences, The University of Manchester. His academic journey includes a Doctor of Philosophy (2018) from the University of Manchester, an MRes in Protein Biochemistry (2011) from Imperial College London, and a BSc in Biology (2009) from the University of York. His research focuses on extracellular matrix (ECM) biology, proteomics, and skin health. Key areas include collagen remodeling under radiation exposure, UV-induced protein damage, and tetrapeptide matrikines for skin rejuvenation. He has contributed to advancements in spatially resolved proteomics and ECM-associated diagnostics. Eckersley has received notable awards: the Best Poster Award (2017) and Early Career Research Award (2019). He collaborates on projects like the ‘Laser capture dissection for spatially-resolved -omics analysis’ (2024-2025). His work spans over 28 publications and includes datasets on ECM photodamage (2020) and fibrillin microfibril comparisons (2018). His research integrates proteomics, structural biology, and biomedical applications, addressing topics like vascular aging, kidney ECM remodelling, and circadian rhythms in skin cells. Eckersley’s contributions bridge fundamental ECM science with translational biomedical innovations.

• Mitochondrial Biology
• Exercise Physiology
• Muscle Injury and Recovery
• +4 more

Junwon Heo is a researcher affiliated with the University of Georgia's College of Veterinary Medicine. His work focuses on mitochondrial function in health and disease, particularly in contexts of muscle injury, aging, exercise physiology, and metabolic disorders. He explores mechanisms linking mitochondrial dysfunction to conditions like sarcopenia, cardiac aging, and neurodegenerative processes. His research employs animal models (e.g., mice, rats) to investigate interventions such as exercise training, pharmacological agents (e.g., resveratrol, SS-31), and biomaterials to mitigate mitochondrial damage and promote tissue repair. Key areas of investigation include: Mitochondrial bioenergetics and oxidative stress in muscle and cardiac tissues Sex/gender differences in physiological responses to injury and diet Effects of Western-style diets on musculoskeletal and metabolic health Role of exercise as a therapeutic strategy for aging-related conditions Development of regenerative rehabilitation approaches for volumetric muscle loss Recent studies highlight the translational potential of his work, including identifying resveratrol's cardioprotective effects in aging hearts and demonstrating vibration therapy's efficacy in muscle regeneration. His methodologies include advanced mitochondrial function assays, such as the CK clamp technique, to quantify bioenergetic changes in brain and muscle tissues. While no specific academic awards are mentioned, his publication record reflects a sustained focus on mechanistic studies of mitochondrial dysfunction and translational rehabilitation strategies. Collaborations with institutions like PDRC (likely the Program in Developmental Rehabilitation) and involvement in grant-funded projects suggest active participation in interdisciplinary research networks.